Liquid biopsy and what insurers need to know

“Liquid biopsy” is a new molecular technology being explored for its use in helping to treat – and detect – cancer. While the new test could ultimately benefit cancer patients and improve survival outcomes, it also creates new risks and exposures for life and health insurers, particularly for critical illness and cancer products.

Read more